US 12,186,375 B2
Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
Jennifer A. Dumont, Groton, MA (US); Susan Low, Pepperill, MA (US); Alan J. Bitonti, Acton, MA (US); Glenn Pierce, Rancho Santa Fe, CA (US); Alvin Luk, Boston, MA (US); Haiyan Jiang, Belmont, MA (US); Byron McKinney, San Diego, CA (US); Matt Ottmer, Newton, MA (US); Jurg Sommer, Wayland, MA (US); Karen Nugent, Owlswick (GB); Lian Li, Lexington, MA (US); and Robert T. Peters, Needham, MA (US)
Assigned to BIOVERATIV THERAPEUTICS INC., Waltham, MA (US)
Filed by Bioverativ Therapeutics Inc., Waltham, MA (US)
Filed on Dec. 4, 2020, as Appl. No. 17/112,280.
Application 15/991,629 is a division of application No. 14/131,600, granted, now 10,010,622, issued on Jul. 3, 2018, previously published as PCT/US2012/045784, filed on Jul. 6, 2012.
Application 17/112,280 is a continuation of application No. 15/991,629, filed on May 29, 2018, granted, now 10,881,742.
Claims priority of provisional application 61/657,641, filed on Jun. 8, 2012.
Claims priority of provisional application 61/622,789, filed on Apr. 11, 2012.
Claims priority of provisional application 61/586,443, filed on Jan. 13, 2012.
Claims priority of provisional application 61/569,158, filed on Dec. 9, 2011.
Claims priority of provisional application 61/541,561, filed on Sep. 30, 2011.
Claims priority of provisional application 61/522,647, filed on Aug. 11, 2011.
Claims priority of provisional application 61/506,015, filed on Jul. 8, 2011.
Prior Publication US 2021/0220476 A1, Jul. 22, 2021
Int. Cl. A61K 38/37 (2006.01); A61K 47/60 (2017.01); A61K 47/68 (2017.01); C07K 14/755 (2006.01); G01N 33/86 (2006.01)
CPC A61K 38/37 (2013.01) [A61K 47/60 (2017.08); A61K 47/68 (2017.08); C07K 14/755 (2013.01); G01N 33/86 (2013.01); C07K 2319/00 (2013.01); C07K 2319/31 (2013.01)] 19 Claims
 
1. A method for treating a subject in need of surgical prophylaxis, peri-operative management, or treatment for surgery, comprising administering to the subject a therapeutic dose of a chimeric polypeptide, the chimeric polypeptide comprising a Factor VIII portion and a second portion, wherein said Factor VIII portion comprises processed Factor VIII and single chain Factor VIII, wherein about 10% to about 40% of the Factor VIII portion is single chain Factor VIII; wherein the chimeric polypeptide is administered at a dosing interval of between about 12 hours and 24 hours; wherein the subject has hemophilia A.